A POWERFUL RESEARCH AND
DEVELOPMENT ENGINE

Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

Interact with the Regeneron Pipeline

Pipeline last updated:
Select Therapeutic Area(s):
Select Phase(s):
Select Collaborator(s):

Displaying item(s)

Clear Filters

Phase 1 trials Phase 1 trials
  • CEMIPLIMAB*
    PD-1 Antibody Cancer
  • REGN3767
    LAG-3 Antibody Cancer
  • REGN1979
    CD20xCD3 Antibody Cancer
  • REGN4018*
    MUC16xCD3 Antibody Cancer
  • REGN5093
    METxMET Antibody Cancer
  • REGN5458*
    BCMAxCD3 Antibody Cancer
  • REGN5459*
    BCMAxCD3 Antibody Cancer
  • REGN5678
    PSMAxCD28 Antibody Cancer
  • REGN5713-5714-5715
    Betv1 Antibody Birch Allergy
Phase 2 trials Phase 2 trials
  • CEMIPLIMAB*
    PD-1 Antibody Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)
  • AFLIBERCEPT
    VEGF Trap High-dose for wet age-related macular degeneration (AMD)
  • REGN1979
    CD20xCD3 Antibody Relapsed/refractory follicular lymphoma, non-Hodgkin lymphomas, diffuse large B-cell lymphoma
  • DUPILUMAB*
    IL-4R Antibody Grass allergy, peanut allergy
  • SARILUMAB*
    IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis
  • REGN1908-1909
    Fel d 1 Antibody Cat allergy
  • REGN3500*
    IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis
  • REGN5069
    GFRα3 Antibody Osteoarthritis knee pain
  • REGN4461
    LEPR Antibody Generalized lipodystrophy
  • GARETOSMAB
    Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)
  • EVINACUMAB
    ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia
  • POZELIMAB
    C5 Antibody Paroxysmal nocturnal hemoglobinuria
Phase 3 trials Phase 3 trials
  • AFLIBERCEPT
    VEGF Trap Retinopathy of Prematurity (ROP)
  • ALIROCUMAB*
    PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics
  • CEMIPLIMAB*
    PD-1 Antibody Non-small cell lung cancer (NSCLC), cervical cancer, cutaneous squamous cell carcinoma (CSCC) (adjuvant)
  • REGN-EB3
    Ebola Virus Antibody Ebola virus infection
  • DUPILUMAB*
    IL-4R Antibody Atopic dermatitis in pediatrics, asthma in pediatrics, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), prurigo nodularis, bullous pemphigoid, chronic spontaneous urticaria
  • SARILUMAB*
    IL-6R Antibody Polymyalgia rheumatica, giant cell arteritis
  • EVINACUMAB
    ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)
  • FASINUMAB†
    NGF Antibody Chronic pain from osteoarthritis of the knee or hip

No results found, please adjust your filter selection and try again.

* In collaboration with Sanofi

† In collaboration with Teva and Mitsubishi Tanabe

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.